Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: In the first course, hematological toxicity was observed and host QOL and immune function were exacerbated. In the second course, however, the number of white blood cells and lymphocytes did not decrease and host QOL was maintained. Furthermore, the cytotoxic activities of natural killer (NK) and lymphokine-activated killer cells and the proportion of activated NK and NK T-cells in lymphocytes were maintained in the second course. CONCLUSION: It has been suggested that the concomitant use of LEM with FEC75 therapy can maintain host QOL and immune function, and offer important implications for an application of LEM as a useful oral adjuvant to anthracycline-based chemotherapies.
|
Authors | Yukiko Nagashima, Noriko Maeda, Shigeru Yamamoto, Shigefumi Yoshino, Masaaki Oka |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 6
Pg. 853-9
( 2013)
ISSN: 1178-6930 [Print] New Zealand |
PMID | 23874107
(Publication Type: Journal Article)
|